Physician profile
Gemma C Meadows
NPI 1114913381
$1,369.72
in general payments reported to CMS, 2019-2025
13 companies · $518 in 2025
The $518 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.17 · 2020: $73.34 · 2021: $277 · 2022: $124 · 2023: $209 · 2024: $119 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813 · Entertainment: $32.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.80 |
| Entertainment | $32.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $500.30 | 2019-2025 | Dailies Total1, Precision7, Total30 |
| Johnson & Johnson Vision Care, INC. | $252.79 | 2020-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $180.76 | 2021-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $138.08 | 2021 | |
| Bausch & Lomb Americas INC. | $66.32 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $48.49 | 2021 | |
| Novartis Pharmaceuticals Corporation | $40.74 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $36.88 | 2025 | Xdemvy |
| Optos, INC. | $32.85 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Thea Pharma INC. | $24.94 | 2025 | Iyuzeh |
| Coopervision INC. | $17.46 | 2023 | Myday Contact Lens |
| Shire North American Group INC | $15.17 | 2019 | |
| Lkc Technologies, INC. | $14.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gemma Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.